abrocitinib + metformin

A **combination of abrocitinib (PF-04965842)**, an oral selective Janus kinase 1 (JAK1) inhibitor, and **metformin**, an oral antidiabetic agent in the biguanide class. Abrocitinib inhibits JAK1-mediated signal transduction, interfering with cytokine signaling that contributes to inflammatory diseases, especially atopic dermatitis and potentially other autoimmune disorders[1][2][5][6]. Metformin decreases hepatic glucose production, increases insulin sensitivity, and enhances peripheral glucose uptake; it is widely approved and used for type 2 diabetes. The combination has been studied in healthy subjects to evaluate potential pharmacokinetic interactions, with evidence indicating a low risk of significant drug-drug interaction[3]. There is currently no evidence that this combination is approved or used clinically as a fixed-dose or branded pharmaceutical product. The combination may be of investigational or research interest, particularly in settings where abrocitinib is being administered to patients with type 2 diabetes or metabolic disturbances.

Other names

abrocitinibPF-04965842PF04965842PF 04965842